Quality of Life Study in Participants With IPF Under Pirfenidone Treatment
- Respiratory Disorder
- Idiopathic Pulmonary Fibrosis (IPF)
Completed
- Greece
NCT03115619 ML39259
Trial Summary
This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).
A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study
Eligibility Criteria
- Adult participants for whom pirfenidone has already been prescribed for IPF no more than 4 weeks prior to enrollment, according to their physicians' clinical decision and the terms in the SmPC
- Participants who are participating in an interventional study or have received any investigational agent in the past 4 weeks
For the latest version of this information please go to www.forpatients.roche.com